


REMARKS

Claims 1-8 and 12-27 are pending. The Examiner has required restriction under 35 U.S.C. § 121 to one of four groups. (Office Action, page 2). Applicants elect, without traverse, group I, drawn to compounds of Formula (I) and compositions thereof, *i.e.*, claims 1-8, 14-20 and 25-27. Applicants elect the following species to be examined:

[5-(4-{[4-(trifluoromethyl)benzoyl]amino}benzyl)imidazo[1,2-c]pyrimidin-8-yl]acetic acid, which has the structure




This compound is Example 2-1 at page 42 of the specification. Claims 1-8, 14-20 and 26-27 read on the elected species. Applicants reserve the right to file divisional or continuation applications directed to any canceled subject matter. Applicants also reserve the right to request rejoinder of the claims of the non-elected groups pursuant to M.P.E.P. § 821.04.

No fees are believed due in connection with this Response. However, pursuant to 37 C.F.R. § 1.136(a)(3), the Commissioner is authorized to charge all required fees, fees under 37 C.F.R. § 1.17, and all required extension of time fees, or credit any overpayment, to Jones Day, U.S. Deposit Account No. 503013 (Order No. 129955-999006).

If the Examiner believes it would be useful to advance prosecution, the Examiner is invited to telephone the undersigned at (858) 314-1200.

Respectfully submitted,

Date: July 2, 2009


Mark D. Kafka
For: Dale L. Rieger

Reg. No. 59,569
Reg. No. 43,045

JONES DAY
222 East 41st Street
New York, New York 10017
(858) 314-1200